HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hughes, J R Articles by Zhang, J Search for Related Content PubMed PubMed Citation Articles by Hughes, J R Articles by Zhang, J

A meta-analysis of the efficacy of over-the-counter nicotine replacement

¹ Department of Psychiatry, University of Vermont, Burlington, Vermont, USA
² Pinney Associates and the University of Pittsburgh, Pittsburgh, Pennsylvania, USA
³ Medical Biostatistics, University of Vermont

Correspondence to: John R Hughes, MD, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401, USA; john.hughes{at}uvm.edu

Objective: To determine whether over-the-counter (OTC) nicotine replacement therapy (NRT) is pharmacologically efficacious, whether it produces abstinence rates similar to those in prescription settings, and to estimate the long term (that is, greater than six month) abstinence rate with OTC NRT.

Method: Systematic literature review.

Data sources: Medline, Psych Abstracts, bibliographies, requests of scientists.

Study selection: Studies comparing OTC NRT versus OTC placebo or studies comparing OTC NRT versus prescription NRT that reported abstinence rates and for which a full study report was available.

Data extraction: Two of the authors independently reviewed studies and compared results.

Data synthesis: Meta-analysis was performed by first testing for homogeneity across studies, then combining odds ratios (ORs) weighting by inverse variance and proportions weighting by study sample size.

Results: One OTC NRT versus OTC placebo nicotine gum study was excluded due to small sample size and different setting. The four remaining studies were randomised trials of nicotine versus placebo patch with ORs of 2.1–3.2. These outcomes were homogenous and when combined resulted in an OR favouring NRT of 2.5 (95% confidence interval (CI) 1.8 to 3.6). Among the two randomised and two non-randomised trials of OTC NRT versus prescription NRT, one small study had an OR of 0.3, two others had ORs of 1.0 and 1.4, and a fourth study had an OR of 3.6. These results were not homogenous; however, when combined via a random effects model the estimated OR was not less than 1.0—that is, OR 1.4 (95% CI 0.6 to 3.3). The long term (that is, greater than six months) quit rates for OTC NRT was 1% and 6% in two studies and 8–11% in five other studies. These results were not homogenous; however, when combined the estimated OR was 7% (95% CI 4% to 11%).

Conclusions: OTC NRT is pharmacologically efficacious and produces modest quit rates similar to that seen in real world prescription practice.

Keywords: meta-analysis; nicotine; nicotine gum; cessation; tobacco use disorder; transdermal nicotine

Abbreviations: CI, confidence interval; NRT, nicotine replacement therapy; OTC, over-the-counter; OR, odds ratio

This article has been cited by other articles:

				J. F Hollis, T. A McAfee, J. L Fellows, S. M Zbikowski, M. Stark, and K. Riedlinger The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline Tob. Control, December 1, 2007; 16(Suppl_1): i53 - i59. [Abstract] [Full Text] [PDF]

				R. West and X. Zhou Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study Thorax, November 1, 2007; 62(11): 998 - 1002. [Abstract] [Full Text] [PDF]

				P. Aveyard, K. Brown, C. Saunders, A. Alexander, E. Johnstone, M. R Munafo, and M. Murphy Weekly versus basic smoking cessation support in primary care: a randomised controlled trial Thorax, October 1, 2007; 62(10): 898 - 903. [Abstract] [Full Text] [PDF]

				J.-F. Etter and J. A Stapleton Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob. Control, August 1, 2006; 15(4): 280 - 285. [Abstract] [Full Text] [PDF]

				A. M. Lee and R. F. Tyndale Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 7 - 14. [Abstract] [PDF]

				S Shiffman, M E Di Marino, and C T Sweeney Characteristics of selectors of nicotine replacement therapy Tob. Control, October 1, 2005; 14(5): 346 - 355. [Abstract] [Full Text] [PDF]

				S Shiffman, J R Hughes, J L Pillitteri, and S L Burton Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample Tob. Control, September 1, 2003; 12(3): 310 - 316. [Abstract] [Full Text] [PDF]

				H. Marcovitch BMJ family highlights BMJ, May 10, 2003; 326(7397): 1005 - 1005. [Full Text] [PDF]

eLetters: